NCT06852625View on ClinicalTrials.gov

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Kidney Transplant Rejection
Interventions
BIOLOGICAL

Autologous Tolerogenic Dendritic Cells

• Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and Day 3 after transplantation.

Trial Locations (7)

50009

Hospital Universitario Miguel Servet, Zaragoza

08916

Hospital Germans Trias i Pujol, Badalona

08003

Hospital del Mar, Barcelona

08025

Fundació Puigvert, Barcelona

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clinic Barcelona, Barcelona

08907

Hospital Universitari Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
lead

Fundacion Clinic per a la Recerca Biomédica

OTHER